Johnson & Johnson Acquires Intra-Cellular Therapies to Bolster Mental Health Business

Posted on by admin

Acquisition includes Caplyta, a once-daily oral therapy approved for schizophrenia and bipolar depression.

Leave a Reply

Your email address will not be published. Required fields are marked *